JP2015513535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513535A5 JP2015513535A5 JP2014558090A JP2014558090A JP2015513535A5 JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5 JP 2014558090 A JP2014558090 A JP 2014558090A JP 2014558090 A JP2014558090 A JP 2014558090A JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- phosphatidylserine
- use according
- receptor
- tim
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 claims 27
- 239000003112 inhibitor Substances 0.000 claims 26
- 102100016385 HAVCR1 Human genes 0.000 claims 7
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 7
- 108091005706 TAM receptors Proteins 0.000 claims 6
- 230000003993 interaction Effects 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 230000000840 anti-viral Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 241000710831 Flavivirus Species 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091006066 receptor inhibitors Proteins 0.000 claims 3
- 241000710929 Alphavirus Species 0.000 claims 2
- 101710010268 CAVIN2 Proteins 0.000 claims 2
- 102100015175 CAVIN2 Human genes 0.000 claims 2
- 101700018422 GAS6 Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 101700004638 ANXA5 Proteins 0.000 claims 1
- 102100007808 ANXA5 Human genes 0.000 claims 1
- 241001502567 Chikungunya virus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 101710004394 HAVCR1 Proteins 0.000 claims 1
- 102100016384 HAVCR2 Human genes 0.000 claims 1
- 101710004393 HAVCR2 Proteins 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 102100002606 TIMD4 Human genes 0.000 claims 1
- 101700055599 TIMD4 Proteins 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 101710031202 tpiA1 Proteins 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Claims (17)
- ウイルス感染を予防または治療するための使用のための、ホスファチジルセリンとＴＩＭレセプターとの間の相互作用の阻害剤であって、
（ｉ）ＴＩＭレセプター阻害剤、および／または
（ｉｉｉ）ホスファチジルセリン結合タンパク質
である阻害剤。 - ＴＩＭレセプターが、ＴＩＭ−１、ＴＩＭ−３またはＴＩＭ−４である、請求項１（ｉ）記載の使用のための阻害剤。
- ＴＩＭレセプター阻害剤が、抗ＴＩＭレセプター抗体、アンチセンス核酸、模倣体または変異型ＴＩＭレセプターである、請求項１または２記載の使用のための阻害剤。
- ホスファチジルセリン結合タンパク質が、抗ホスファチジルセリン抗体またはアネキシン５である、請求項１または２記載の使用のための阻害剤。
- ＴＩＭレセプター阻害剤が、配列番号１、２、３、または４の配列のｓｉＲＮＡである、請求項３記載の使用のための阻害剤。
- ウイルスがホスファチジルセリン保有ウイルスである、請求項１記載の使用のための阻害剤。
- ホスファチジルセリン保有ウイルスが、アルファウイルスまたはフラビウイルスである、請求項１〜６のいずれか一項記載の使用のための阻害剤。
- アルファウイルスがチクングニヤウイルスである、請求項７記載の使用のための阻害剤。
- フラビウイルスが、ウエストナイルウイルス、黄熱ウイルスまたはデング熱ウイルスである、請求項７記載の使用のための阻害剤。
- 前記阻害剤が、少なくとも１種の他の抗ウイルス化合物と組み合わせて連続的または同時のいずれかで投与するための、請求項１〜９のいずれか一項記載の使用のための阻害剤。
- 他の抗ウイルス化合物が、ホスファチジルセリンとＴＡＭレセプターとの相互作用の阻害剤である、請求項１０記載の使用のための阻害剤。
- ホスファチジルセリンとＴＡＭレセプターとの相互作用の阻害剤が、
（ｉ）ＴＡＭレセプター阻害剤、および／または
（ｉｉ）Ｇａｓ６阻害剤
である、請求項１１記載の使用のための阻害剤。 - 前記阻害剤が、薬学的に許容されうる組成物に製剤化される、請求項１〜１２のいずれか一項記載の使用のための阻害剤。
- 請求項１〜９のいずれか一項記載の阻害剤および追加的に少なくとも１種の他の抗ウイルス化合物を含む薬学的組成物。
- 少なくとも１種の他の抗ウイルス化合物が、ホスファチジルセリンとＴＡＭレセプターとの相互作用の阻害剤である、請求項１４記載の薬学的組成物。
- ホスファチジルセリンとＴＡＭレセプターとの相互作用の阻害剤が、
（ｉ）ＴＡＭレセプター阻害剤、および／または
（ｉｉ）Ｇａｓ６阻害剤
である、請求項１５記載の薬学的組成物。 - 細胞内へのホスファチジルセリン保有ウイルス、特にフラビウイルスの侵入を阻害するin vitro方法における、請求項１〜９のいずれか一項記載の阻害剤の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305193 | 2012-02-21 | ||
| EP12305193.0 | 2012-02-21 | ||
| EP12306281 | 2012-10-17 | ||
| EP12306281.2 | 2012-10-17 | ||
| PCT/EP2013/053391 WO2013124327A1 (en) | 2012-02-21 | 2013-02-20 | Tim receptors as virus entry cofactors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015513535A JP2015513535A (ja) | 2015-05-14 |
| JP2015513535A5 true JP2015513535A5 (ja) | 2016-03-10 |
Family
ID=47739275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558090A Pending JP2015513535A (ja) | 2012-02-21 | 2013-02-20 | ウイルス侵入補助因子としてのｔｉｍレセプター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160017035A1 (ja) |
| EP (1) | EP2817327A1 (ja) |
| JP (1) | JP2015513535A (ja) |
| BR (1) | BR112014021068A8 (ja) |
| IN (1) | IN2014DN07023A (ja) |
| MX (1) | MX2014010016A (ja) |
| WO (1) | WO2013124327A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN07022A (ja) | 2012-02-21 | 2015-04-10 | Inst Nat Sante Rech Med | |
| WO2014093627A2 (en) * | 2012-12-13 | 2014-06-19 | Children's Medical Center Corporation | Compositions and methods for inhibiting viral entry |
| US20170000849A1 (en) * | 2013-12-20 | 2017-01-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cd300a receptors as virus entry cofactors |
| WO2016059146A1 (en) * | 2014-10-15 | 2016-04-21 | Annexin Pharmaceuticals Ab | Therapeutic composition comprising annexin v |
| KR102582192B1 (ko) * | 2014-12-05 | 2023-09-25 | 후지필름 가부시키가이샤 | Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트 |
| SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| US20210024582A1 (en) * | 2018-03-29 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric tim-3 fusion protein |
| US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993023569A1 (en) | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| EP0918790B1 (en) | 1996-05-24 | 2004-01-28 | Ic-Vec Limited | Polycationic sterol derivatives as transfection agents |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| JP2003525017A (ja) | 1998-04-20 | 2003-08-26 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 遺伝子発現を調節しうる新規な化学組成を有する核酸分子 |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| AU2001268159B2 (en) | 2000-06-02 | 2005-09-15 | Eisai Inc. | Delivery systems for bioactive agents |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| HUP0303616A3 (en) | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| JP2004535388A (ja) | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | 脂質含有薬物送達複合体およびそれらの生成方法 |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| EP1575976A4 (en) | 2001-11-02 | 2006-08-23 | Insert Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE |
| WO2003057190A1 (en) | 2001-12-31 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| EP1480657A4 (en) | 2002-02-01 | 2006-07-05 | Intradigm Corp | POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1476492A1 (en) | 2002-02-22 | 2004-11-17 | Insert Therapeutics Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| WO2003083443A2 (en) | 2002-03-29 | 2003-10-09 | University Of Florida | Lipid mediated screening of drug candidates for identification of active compounds |
| WO2003099225A2 (en) | 2002-05-24 | 2003-12-04 | Mirus Corporation | Compositions for delivering nucleic acids to cells |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| WO2009001224A2 (en) | 2007-06-22 | 2008-12-31 | Eth Zurich | Antivirals |
| WO2009062112A2 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
| CN102256617B (zh) | 2008-10-17 | 2015-04-08 | 伦敦健康科学中心研究公司 | 膜联蛋白及其治疗炎性病症的用途 |
| WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| IN2014DN07022A (ja) | 2012-02-21 | 2015-04-10 | Inst Nat Sante Rech Med |
-
2013
- 2013-02-20 IN IN7023DEN2014 patent/IN2014DN07023A/en unknown
- 2013-02-20 MX MX2014010016A patent/MX2014010016A/es unknown
- 2013-02-20 US US14/379,879 patent/US20160017035A1/en not_active Abandoned
- 2013-02-20 EP EP13704966.4A patent/EP2817327A1/en not_active Withdrawn
- 2013-02-20 JP JP2014558090A patent/JP2015513535A/ja active Pending
- 2013-02-20 BR BR112014021068A patent/BR112014021068A8/pt not_active IP Right Cessation
- 2013-02-20 WO PCT/EP2013/053391 patent/WO2013124327A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513535A5 (ja) | ||
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| WO2015042308A3 (en) | Rna-based hiv inhibitors | |
| GT201500086A (es) | Análogos de 2'-cloro nucleósido para infección por vhc | |
| JP2014519662A5 (ja) | ||
| JP2012126742A5 (ja) | ||
| JP2017070307A5 (ja) | ||
| JP2018530530A5 (ja) | ||
| CO7170127A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos | |
| JP2015516989A5 (ja) | ||
| BRPI0813237B8 (pt) | composto, método para preparar o composto, medicamento, e, uso do composto | |
| JP2016513638A5 (ja) | ||
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| JP2011528896A5 (ja) | ||
| WO2008014979A3 (en) | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | |
| JP2013539454A5 (ja) | ||
| JP2011528895A5 (ja) | ||
| WO2013006795A3 (en) | Antiviral compositions and methods of their use | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| JP2015526391A5 (ja) | ||
| CL2011001977A1 (es) | Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades. | |
| JP2013503110A5 (ja) | ||
| JP2011528897A5 (ja) | ||
| JP2014503593A5 (ja) | ||
| ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. |